Results: TPTD reduced vertebral and nonvertebral fracture risk, increased lumbar spine and femoral neck BMD, and increased PINP relative to placebo in the two 25OHD subgroups. There were no significant differences in these endpoints between the subgroups (each treatment by-subgroup interaction p > 3 0.10). However, it should be noted that because of the limited number of fractures, this study does not exclude the possibility of differences in fracture outcome between the subgroups.
Introduction
Vitamin D is essential for maintaining calcium homeostasis and optimizing bone health. Low concentrations of vitamin D lead to alterations in calcium and phosphorus homeostasis, secondary hyperparathyroidism, bone loss, osteoporosis, and an increase in fracture risk (1) (2) (3) . More severe degrees of vitamin D deficiency may lead to impairment of bone mineralization and osteomalacia (4) . Additionally, low serum concentrations of 25-hydroxyvitamin D (25OHD), have recently been associated with impaired lower extremity strength and performance (5) . Adequate calcium and vitamin D intake is considered an essential component of osteoporosis management (6) .
Numerous epidemiological studies have assessed the prevalence of low serum 25OHD (7) (8) (9) (10) and found that vitamin D inadequacy is a common problem worldwide. For example, more than half of North American women receiving therapy to treat or prevent osteoporosis have 25OHD inadequacy (10) .
Worldwide, over one billion people may have vitamin D deficiency or insufficiency (11) .
Recently, it has been postulated that having vitamin D insufficiency might impair the therapeutic response to osteoporosis therapy. One study has suggested that without pharmacological vitamin D replacement, etidronate confers smaller increases in bone mineral density (BMD) in patients with vitamin D insufficiency versus sufficiency (12) . However, two recent studies showed raloxifene and alendronate, when co-administered with calcium and vitamin D supplementation, conferred similar increases in BMD in patients with vitamin D insufficiency versus sufficiency (13, 14) .
Teriparatide [rhPTH , TPTD] is a bone anabolic drug with an essentially opposite mechanism of action from that of antiresorptive drugs (15) . While antiresorptive drugs decrease bone turnover by inhibiting resorption, teriparatide increases bone turnover with a positive balance of bone formation versus resorption. In postmenopausal women with osteoporosis, the clinical effects of teriparatide include increases in lumbar spine and femoral neck BMD and reduced vertebral and nonvertebral fracture risk (16) . This analysis was conducted to determine whether it is important to normalize serum 25OHD prior to TPTD initiation or whether the same benefits of therapy can be achieved by initiating supplementation around the time that therapy is initiated. Given that women with osteoporosis commonly have inadequate vitamin D concentrations, the current analysis explores the fracture risk reduction, BMD, and bone turnover marker responses to teriparatide in women with 25OHD sufficiency versus insufficiency at baseline.
Materials and Methods

Study population
Data from the multicenter Fracture Prevention Trial (FPT) were used in this analysis. The methods and results of the FPT have been previously published non-significant abnormal laboratory values, with specific requirements that serum calcium, serum endogenous parathyroid hormone (PTH), and urinary calcium excretion be within normal limits. The number of women excluded because of elevated serum calcium or PTH levels is unknown. By protocol, patients with serum 25OHD <10 ng/ml or >183 ng/ml (three times the upper limit of the reference range) at randomization were excluded. Even so, 6 patients had serum 25OHD less than 10 ng/ml at baseline; these patients were excluded from the current analysis. The median duration of exposure to teriparatide was 19 months and the median duration of observation was 21 months.
Fracture assessment
Thoracic and lumbar spine radiographs were performed at baseline and study endpoint. Radiographs were assessed at a central site (Osteoporosis and Arthritis Research Center, University of California San Francisco, San Francisco, CA, USA) by radiologists who were blinded to treatment, using a visual semiquantitative (SQ) technique (17). A new vertebral fracture was reported for vertebrae not fractured at baseline with approximately 20% or greater height loss at follow-up. Nonvertebral fractures were documented by a review of the radiographs or radiologic reports and were classified as fragility fractures if the associated trauma would not have resulted in the fracture of a normal bone, in the opinion of the local investigator. Protocol-specified nonvertebral sites included clavicle, scapula, rib, sacrum, humerus, forearm, carpus, pelvis, femur, patella, tibia, fibula, ankle, calcaneus, tarsus, and metatarsal.
BMD assessment
Lumbar spine and femoral neck BMD were assessed by dual-energy X-ray absorptiometry (DXA) using Hologic (Hologic Corp., Bedford, MA, USA), Norland (Norland Corp., Ft. Atkinson, W Corp., Madison, WI, USA), and GE-Lunar (Lunar Corp., Madison, WI, USA) equipment. To eliminate differences attributable to densitometer manufacturer, BMD values were converted to standardized units (expressed as grams per square centimeter). BMD measurements were analyzed centrally by persons blinded to treatment. Vertebrae that could not be analyzed due to prevalent vertebral fractures apparent on the DXA screen, surgical artifact, excessive osteophytes, or other permanent artifact were excluded from the analysis. Serial measurements of a spine phantom at each center were used to adjust for minor changes in densitometer performance and to assess the consistency of measurements between centers.
Laboratory analyses
Bone formation marker amino-terminal propeptide of type I procollagen (PINP) was used for this analysis because this marker had the highest signal-to-noise ratio of those assessed in the FPT (18), and 3-month changes in this biomarker were correlated with lumbar spine BMD response at 18 months (19). Baseline and 3-month PINP assessments were performed on a subset of 771 patients.
The baseline demographics of this PINP subset were not significantly different from those of the overall study population (19). Serum samples were stored at -20ºC at Covance Central Laboratories, Inc., (Indianapolis, IN, USA) and later shipped to SUPREME SA (Liege, Belgium) for testing using the UniQ assay (Orion Diagnostica, Espoo Finland; intra-assay CV, 4.8% -13.7%; inter-assay CV, 3.1% -8.2%) by persons blinded to group assignment.
Samples for serum calcium were collected at baseline and at approximately 4 to 6 hours after the previous injection (post-dose) of study drug at 1, 3, 6, 12, and 18 months, as well as at early discontinuation and study closeout visits from had serum concentrations ≥2.76 mmol/L. Previously serum calcium levels were found to be maximal at 4 to 6 hours after TPTD injections (post-dose) (16) .
Fasting blood samples for assessment of 25OHD were obtained at a screening visit prior to initiation of calcium and vitamin D supplementation, at the baseline randomization visit at least 1 month after initiation of calcium and vitamin D supplements and 12 months after randomization. Samples were centrifuged and serum was frozen until analyzed. Serum 25OHD was measured by RIA (DiaSorin, Stillwater, MN, USA) with an inter-assay coefficient of variation (CV) between 2.7% and 6.0%.
Statistical analysis
25OHD concentrations at the baseline (randomization) visit were defined as "insufficient" if they were >10 ng/ml (25 nmol/liter) and ≤30 ng/ml (75 nmol/liter), and were defined as "sufficient" if they were >30 ng/ml (75 nmol/liter). Binary 
Results
Demographics
Of 1620 women for whom 25OHD was measured at randomization, 767 (47.3%) had 25OHD insufficiency. There were no other significant differences in baseline characteristics between the treatment groups among the women with sufficient or insufficient 25OHD concentrations. Body mass index (BMI) values tended to be higher in women with sufficient 25OHD concentrations compared to those with insufficient 25OHD (Table 1) , but these differences were not statistically significant.
Change in vitamin D status
The vitamin D status of 1409 patients who had assessments at screening, randomization, and 12 months are provided in Table 2 . At screening, 4% to 6% of participants were vitamin D deficient and 55% to 60% were insufficient. At randomization, after approximately a month of calcium and vitamin D supplementation, very few were deficient, but approximately 50% remained insufficient. After 12 months of vitamin D supplementation and study drug, there was no significant change in the proportion of patients with 25OHD deficiency and insufficiency versus randomization in the placebo group, while in the TPTD20 and TPTD40 groups, about 67% of women were 25OHD insufficient.
The proportions of women with 25OHD insufficiency were significantly greater at 12 months compared to values at baseline (randomization) ( Table 2) 
Incidence of elevated serum calcium levels
The effects of baseline 25OHD status on the incidence of at least one occurrence of elevated serum calcium concentrations ≥2.76 mmol/L at 4 to 6 hour post-dose) are presented in Figure 4 . In women with sufficient or insufficient 25OHD
concentrations, there was a significantly higher incidence of elevated serum calcium with TPTD40 treatment compared to the placebo-and TPTD20-treated groups. There was no significant difference in the incidence of elevated serum calcium between the TPTD20 and placebo groups. There was no significant difference in the incidence of elevated serum calcium concentrations between women with baseline 25OHD sufficiency and insufficiency (treatment-bysubgroup interaction p = 0.54). ng/ml because it is the level below which serum PTH has been found to rise (10, 25) and it reflects the opinions of 5/6 members of a recent expert panel (26) .
Vitamin D status at other timepoints
The 30 ng/ml cut point is similar to that used in previous analyses (10, (13) (14) .
The baseline characteristics of the subgroups were well matched. Although BMI and serum 25OHD have been found to be inversely related in other studies (27) , BMI tended to be higher in the vitamin D sufficient than in the insufficient group in this study. Possible explanations for this might be that per protocol, a disproportionate number of women with high BMI were excluded from participation on the basis of vitamin D deficiency and increased PTH levels (28, 29, 30) .
There was no significant difference in the effect of teriparatide to reduce the incidence of vertebral and nonvertebral fragility fractures, to increase bone formation as assessed by PINP, and to increase BMD at the lumbar spine and femoral neck in patients with baseline 25OHD sufficiency or insufficiency. The incidence of serum calcium concentrations ≥2.76 mmol/L 4 to 6 hours after dosing was consistent across treatment groups in the two 25OHD subgroups.
Thus, the response to TPTD together with calcium and vitamin D was similar in women with baseline 25OHD sufficiency versus insufficiency.
There were several limitations of the current analysis. Because of the entry criteria used in this study, the present findings apply only to patients having normal intact PTH concentrations and 25OHD levels above 10 ng/ml. The fracture data does show some numerical differences in the difference between TPTD and placebo in the two subgroups. While the treatment-by-subgroup interaction is not statistically significant, the study may have included too few fractures to identify a real difference if one indeed existed. Examination of the confidence interval for the ratio of the odds ratios reveals the possible magnitude of the difference between the groups given the experimental findings. In this study, if the confidence interval for the ratio of the odds ratios between the subgroups includes 1, then the results would not be statistically significant. For vertebral fracture, the 95% confidence interval for the ratio of the odds ratios was 0.23-1.22, so the results were not statistically significant. Similarly, the 95% confidence interval for the ratio of odds ratios between the subgroups for non-vertebral fracture was 0.15-1.29, so those results were also not statistically significant. However, the wide breadth of confidence intervals indicates that one need obviously be cautious about interpreting the nonsignificance. For the fracture outcome, this study does not exclude the possibility of clinically meaningful differences in fracture outcome in patients with vitamin D sufficiency versus insufficiency. However, the similarity of the BMD and marker findings between these subgroups are reassuring that there is unlikely to be a large difference in fracture outcome. The prudent physician will probably delay initiation of osteoporosis treatments including teriparatide in a patient with vitamin D deficiency until a normalized alkaline phosphatase concentration provides evidence of skeletal healing. In agreement with current labeling recommendations, we support the requirement to not initiate teriparatide in patients with unexplained elevations in alkaline phosphatase or elevations in serum calcium prior to treatment. Also consistent with current labeling, we do not support routine measurement of serum PTH prior to treatment. We are aware of no evidence that measuring serum PTH prior to treatment adds value for patients with normal serum calcium and alkaline phosphatase levels. However, as always, physicians may sometimes find assessments of serum PTH concentrations useful in the management of specific patients.
The observation that at entry, 58% of the women in this study had 25OHD insufficiency is in agreement with reports that more than half of North American women receiving therapy to treat or prevent osteoporosis have 25OHD inadequacy (11) . After a month of calcium and vitamin D supplementation and Results from assays for 25OHD are somewhat variable and dependent on the laboratory performing the analysis (33, 34) . Most of the commercial assays tested substantially overestimated serum 25OHD when compared with a gold standard HPLC (34, 35) . Serum 25OHD levels in this study were all measured using the DiaSorin RIA in a single centralized laboratory. This assay has compared well to the gold standard of HPLC (33, 36) .
In postmenopausal women with osteoporosis and normal intact PTH supplemented with vitamin D, the response to TPTD was similar in patients with baseline 25OHD insufficiency or sufficiency. 
